Navigation Links
Study helps explain increased melanoma risk in individuals with red hair
Date:8/22/2013

BOSTON -- A person's skin pigment, which determines hair color and skin tone, is influenced by the melanocortin-1 (MC1R) gene receptor. For the population's one to two percent of redheads, a mutation in MC1R accounts for their red hair color and typical light skin.

Now researchers from Beth Israel Deaconess Medical Center (BIDMC) and Boston University School of Medicine (BUSM) have discovered that the same MC1R mutation responsible for the red hair phenotype also promotes an important cancer-causing pathway. The new findings, reported on-line today in the journal Molecular Cell, help to explain the molecular mechanisms that underlie redheads' well-known risk of developing melanoma, providing new insights for treating and preventing this dangerous type of skin cancer.

Melanoma is the least common but the most lethal of skin cancers. Accounting for 75 percent of all skin-cancer deaths, melanoma originates in pigment-producing skin cells called melanocytes. Melanoma is believed to be a multi-step process (melanomagenesis) of genetic mutations that increase cell proliferation, cell differentiation and cell death and increase an individual's susceptibility to ultraviolet (UV) radiation. Two types of UV radiation UVA and UVB can mutate DNA in skin cells and lead to melanoma.

"In this current study, we have demonstrated that the mutation MC1R-RHC promotes the PI3K/Akt signaling pathway when a red-haired individual is exposed to UV radiation," explains co-senior author Wenyi Wei, PhD, an investigator in the Department of Pathology at BIDMC and Associate Professor of Pathology at Harvard Medical School. PI3K/Akt is a well-known cancer-causing pathway, implicated in breast cancer, ovarian cancer and lung cancer.

Previous work by the study's co-senior author Rutao Cui, MD, PhD, a member of the BUSM Department of Dermatology, had demonstrated that MC1R plays a key role in protecting melanocytes from UV-induced DNA damage. In this current study, Wei and Cui wanted to find out how this was happening.

Led by co-first authors, Lixin Wan, PhD, a member of the Wei laboratory at BIDMC and Juxiang Cao, PhD, a member of the Cui lab at BUSM, the scientific team embarked on a series of experiments in both cell cultures and mouse models. Their experiments showed that in normal circumstances, MC1R was binding to PTEN, a well-known tumor suppressor gene. PTEN acts to safeguard against cancer; without PTEN, the end result is elevated signaling in the cancer-causing P13K/Akt pathway.

The team then went on to demonstrate that MC1R-RHC mutations found in red-haired individuals lacked this protective mechanism. "As a result, upon UVB exposure, we saw an increased destruction of PTEN in the mutated pigment cells," says Wei. The team additionally found that in these same MC1R-RHC pigment cells, elevated PI3K/Akt activity was boosting cell proliferation and was synchronizing with another well-known cancer mutation in the BRAF gene (found in nearly 70 percent of human melanomas) to further accelerate cancer development. In support of these results, note Wei and Cui, another research group at Massachusetts General Hospital recently demonstrated that expression of the BRAF gene mutation in the melanocytes of mice carrying a mutated MC1R gene led to a high incidence of invasive melanomas.

"Together, our findings provide a possible molecular mechanism as to why red-haired individuals harboring MC1R mutations are much more susceptible to UV-induced skin damage than individuals with darker skin, resulting in a 10-to100-fold higher frequency of melanoma," says Wei.

The authors note that this newly established link between MC1R and PTEN will be a starting point for future studies, adding that it remains unclear why only MC1R genetic variants linked to the red hair phenotype but not all MC1R variants are unable to bind to PTEN following UV exposure.

"We think that MC1R variants, in combination with mutations in the BRAF gene, could be used as markers of an increased risk of developing melanoma," explains Wei. The authors add that these new findings suggest that drug inhibitors that target the PI3K/Akt signaling pathway might be used in combination with Vemurafenib, a drug that targets the BRAF oncogenic protein, to treat melanoma patients who have both BRAF and MCIR variants.


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related medicine news :

1. UCLA Nursing study suggests focus on lifestyle changes -- not weight loss -- is key to kids health
2. Study finds grandmothers who raise their grandkids struggle with depression
3. Study: Disease caused by repeat brain trauma in athletes may affect memory, mood, behavior
4. Case study collection diagnostic dilemmas hones physicians skills
5. Shocking New CDC Study Confirms U.S. Tick-Borne Disease Epidemic, Shows Lyme Disease Rates 10X Higher than Previously Reported
6. Penn Medicine study shows survivorship care plans empower cancer patients
7. UCLA study suggests iron is at core of Alzheimers disease
8. Brain cancer survival improved following FDA approval of bevacizumab, Mayo study finds
9. The concussed brain at work: fMRI study documents brain activation during concussion recovery
10. Newest Bard IVC Filter Failure Lawsuit Allegations Update: Resource4thePeople Urges Consumers to Review FDA, Research Study Findings about Adverse Events
11. Longest and largest study of insulin pumps to treat type 1 diabetes in children shows they control blood sugar more effectively and with fewer complications than injections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Tampa, FL (PRWEB) , ... December 05, 2016 ... ... Regional Chief Clinical Officer for the Florida Hospital West Florida Region. McGuinness brings ... record in leading and engaging staff, physicians and leaders. , In her new ...
(Date:12/5/2016)... ... December 05, 2016 , ... The legislation – ... direct supervision of a licensed physical therapist, to render care for certain patients. ... treatment plan from a licensed physical therapist (PT) and throughout the treatment cycle ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... to ensure moisture measurements are consistently correct. However, regular performance testing is ... METTLER TOLEDO offers a solution: SmartCal™ . This innovative test substance ...
(Date:12/4/2016)... ... December 02, 2016 , ... ... better access to nutraceuticals and help doctors more efficiently manage their practice. ... practice management software platform for Integrative and Functional Medicine. , The Metabolic ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... at the 2016 Anti-Aging & Beauty Awards at The Aesthetic & ... & Anti-Aging Medicine European Congress (AMEC) brings together the industry’s leading scientific ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , December 5, 2016 According to ... Treatment modalities (Chondrocyte Transplantation, Growth Factor Technology, Tissue Scaffolds, Cell-free composites), ... by MarketsandMarkets, the market is projected to reach USD 779.8 Million ... CAGR of 13.5% during the forecast period of 2016 to 2021. ... ...
(Date:12/5/2016)... 5, 2016 According to a new report published by ... - Global Opportunity Analysis and Industry Forecast, 2014 - 2022", the global surgical ... $5,255 million by 2022, growing at a CAGR of 6.4% from 2016 to ... share. Continue Reading ... ...
(Date:12/5/2016)... PUNE, India , December 5, 2016 /PRNewswire/ ... Market Research, titled, "Global Cancer Biomarkers Market - Global Opportunity ... biomarkers market is projected to reach $15,737 million by 2022 ... from 2016 to 2022. Omic technologies segment accounted for more ... expected to maintain its dominance during the forecast period. ...
Breaking Medicine Technology: